Literature DB >> 9317041

Molecular cloning and characterization of Dr-II, a nonfimbrial adhesin-I-like adhesin isolated from gestational pyelonephritis-associated Escherichia coli that binds to decay-accelerating factor.

T Q Pham1, P Goluszko, V Popov, S Nowicki, B J Nowicki.   

Abstract

Bacterial adhesins play an important role in the colonization of the human urogenital tract. Escherichia coli Dr family adhesins have been found to be frequently expressed in strains associated with pyelonephritis in pregnant females. The tissue receptor for known Dr adhesins has been localized to the short consensus repeat-3 (SCR-3) domain of decay accelerating factor (DAF), a complement regulatory protein. In this report, we identified and cloned draE2, a gene encoding a novel 17-kDa DAF-binding adhesin, Dr-II, from a strain of E. coli associated with acute gestational pyelonephritis. Despite the significant sequence diversity between Dr-II and Dr family adhesins, the receptor of Dr-II was found to be the SCR-3 domain of DAF. Sequence analysis of the 186-amino-acid Dr-II open reading frame revealed significant diversity from other members of the Dr adhesin family, including Dr, AFA-I, AFA-III, and F1845, but only an 8-amino-acid difference in sequence from that of the 17-kDa nonfimbrial adhesin NFA-I of unknown receptor specificity. N-terminal peptide sequencing of the purified adhesin confirmed the identity of the open reading frame and indicated cleavage of a 28-amino-acid signal peptide. Antibodies raised against purified Dr-II adhesin exhibited little or no cross-reactivity to Dr adhesin. Characterization of the biological properties demonstrated that like the Dr adhesins, Dr-II was associated with the ability of E. coli to bind to tubular basement membranes and Bowman's capsule and to be internalized into HeLa cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9317041      PMCID: PMC175617          DOI: 10.1128/iai.65.10.4309-4318.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

Review 1.  Urinary infection in pregnancy.

Authors:  M J Lucas; F G Cunningham
Journal:  Clin Obstet Gynecol       Date:  1993-12       Impact factor: 2.190

2.  Gestational age-dependent distribution of Escherichia coli fimbriae in pregnant patients with pyelonephritis.

Authors:  B Nowicki; M Martens; A Hart; S Nowicki
Journal:  Ann N Y Acad Sci       Date:  1994-08-15       Impact factor: 5.691

3.  Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.

Authors:  K E Coyne; S E Hall; S Thompson; M A Arce; T Kinoshita; T Fujita; D J Anstee; W Rosse; D M Lublin
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

4.  Genetic analysis of the gene cluster encoding nonfimbrial adhesin I from an Escherichia coli uropathogen.

Authors:  R Ahrens; M Ott; A Ritter; H Hoschützky; T Bühler; F Lottspeich; G J Boulnois; K Jann; J Hacker
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

5.  Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction.

Authors:  C Le Bouguenec; M Archambaud; A Labigne
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

6.  Identification and characterization of a gene cluster mediating enteroaggregative Escherichia coli aggregative adherence fimbria I biogenesis.

Authors:  S J Savarino; P Fox; Y Deng; J P Nataro
Journal:  J Bacteriol       Date:  1994-08       Impact factor: 3.490

7.  Expression and detection of pap-, sfa-, and afa-encoded fimbrial adhesin systems among uropathogenic Escherichia coli.

Authors:  F Daigle; J Harel; J M Fairbrother; P Lebel
Journal:  Can J Microbiol       Date:  1994-04       Impact factor: 2.419

8.  Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses.

Authors:  J M Bergelson; M Chan; K R Solomon; N F St John; H Lin; R W Finberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Characterization of plasmid-borne afa-3 gene clusters encoding afimbrial adhesins expressed by Escherichia coli strains associated with intestinal or urinary tract infections.

Authors:  C Le Bouguenec; M I Garcia; V Ouin; J M Desperrier; P Gounon; A Labigne
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

10.  Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction.

Authors:  B Nowicki; A Hart; K E Coyne; D M Lublin; S Nowicki
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  20 in total

1.  Pyelonephritogenic diffusely adhering Escherichia coli EC7372 harboring Dr-II adhesin carries classical uropathogenic virulence genes and promotes cell lysis and apoptosis in polarized epithelial caco-2/TC7 cells.

Authors:  J Guignot; J Breard; M F Bernet-Camard; I Peiffer; B J Nowicki; A L Servin; A B Blanc-Potard
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  Prophylactic herbal therapy prevents experimental ascending urinary tract infection in mice.

Authors:  Yan-Qing Tong; Min Sun; Ying Chi
Journal:  Chin J Integr Med       Date:  2016-07-19       Impact factor: 1.978

3.  Hydrophilic domain II of Escherichia coli Dr fimbriae facilitates cell invasion.

Authors:  Margaret Das; Audrey Hart-Van Tassell; Petri T Urvil; Susan Lea; David Pettigrew; K L Anderson; Alfred Samet; Jozef Kur; Steve Matthews; Stella Nowicki; Vsevolod Popov; Pawel Goluszko; Bogdan J Nowicki
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesin.

Authors:  Pawel Goluszko; Elzbieta Goluszko; Bogdan Nowicki; Stella Nowicki; Vsevolod Popov; Hui-Qun Wang
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 5.  The preterm parturition syndrome.

Authors:  R Romero; J Espinoza; J P Kusanovic; F Gotsch; S Hassan; O Erez; T Chaiworapongsa; M Mazor
Journal:  BJOG       Date:  2006-12       Impact factor: 6.531

6.  Molecular analysis of asymptomatic bacteriuria Escherichia coli strain VR50 reveals adaptation to the urinary tract by gene acquisition.

Authors:  Scott A Beatson; Nouri L Ben Zakour; Makrina Totsika; Brian M Forde; Rebecca E Watts; Amanda N Mabbett; Jan M Szubert; Sohinee Sarkar; Minh-Duy Phan; Kate M Peters; Nicola K Petty; Nabil-Fareed Alikhan; Mitchell J Sullivan; Jayde A Gawthorne; Mitchell Stanton-Cook; Nguyen Thi Khanh Nhu; Teik Min Chong; Wai-Fong Yin; Kok-Gan Chan; Viktoria Hancock; David W Ussery; Glen C Ulett; Mark A Schembri
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

7.  Representational difference analysis between Afa/Dr diffusely adhering Escherichia coli and nonpathogenic E. coli K-12.

Authors:  Anne-Beatrice Blanc-Potard; Colin Tinsley; Isabel Scaletsky; Chantal Le Bouguenec; Julie Guignot; Alain L Servin; Xavier Nassif; Marie-Francoise Bernet-Camard
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55.

Authors:  Sylvie Hudault; O Brad Spiller; B Paul Morgan; Alain L Servin
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 9.  Toll-like receptors and immune response in allergic disease.

Authors:  Sophie C Gangloff; Moncef Guenounou
Journal:  Clin Rev Allergy Immunol       Date:  2004-04       Impact factor: 8.667

10.  Chimeric Dr fimbriae with a herpes simplex virus type 1 epitope as a model for a recombinant vaccine.

Authors:  Beata Zalewska; Rafał Piatek; Grazyna Konopa; Bogdan Nowicki; Stella Nowicki; Józef Kur
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.